Studies presented in this review highlight important scientific discoveries that have molded
our current understanding of the contribution of altered phosphate homeostasis to CKD …

Patients with CKD often progress to ESRD and develop cardiovascular disease (CVD), yet
available therapies only modestly improve clinical outcomes. Observational studies report …

Over the last two decades, scientific developments have enhanced our understanding of the
pathogenesis of cardiovascular disease in patients with CKD, and specific nontraditional risk …

A series of problems including osteopathy, abnormal serum data, and vascular calcification
associated with chronic kidney disease (CKD) are now collectively called CKD-mineral bone …

Background Hyperphosphatemia confers adverse cardiovascular outcomes, and commonly
occurs in late-stage CKD. Fibroblast growth factor 7 (FGF7) is a phosphaturic peptide which …

Hyperphosphataemia is a clinical consequence of the advanced stages of chronic kidney
disease (CKD). Considerable evidence points to a role of hyperphosphataemia in the …

When compared to the available information for patients on dialysis (CKD stage 5D), data on
the epidemiology and appropriate treatment of calcium and phosphate metabolism in the …

Hyperphosphatemia is the most common metabolic complications of end-stage kidney
disease (ESKD). Large observational studies have identified hyperphosphatemia as an …

The kidney plays a central role in the maintenance of phosphorus homeostasis. Thus
disturbance of phosphorus metabolism develops in most patients with chronic kidney …

Hyperphosphatemia is a well-known feature of advanced chronic kidney disease (CKD) and
a major risk factor for cardiovascular events in patients with CKD, inducing calcium …